1 189 163 A RANDOMIZED STUDY OF YOGA FOR FATIGUE AND QUALITY OF LIFE IN WOMEN WITH BREAST CANCER UNDERGOING (NEO) ADJUVANT CHEMOTHERAPY. OBJECTIVES: TO COMPARE THE EFFECTIVENESS OF YOGA ADDED TO STANDARD CARE (SC) VERSUS SC ONLY, IN WOMEN WITH BREAST CANCER DURING CHEMOTHERAPY. DESIGN: A MULTICENTER PRAGMATIC, RANDOMIZED CONTROLLED STUDY. SETTINGS/LOCATION: THREE HOSPITALS IN THE NETHERLANDS. SUBJECTS: WOMEN WITH STAGE I-III BREAST CANCER UNDERGOING CHEMOTHERAPY. INTERVENTIONS: WOMEN WERE RANDOMIZED EITHER TO A PROGRAM BASED ON DRU YOGA, ONCE A WEEK YOGA SESSIONS FOR 12 WEEKS (N = 47), OR SC ONLY (N = 36). OUTCOME MEASURES: PRIMARY OUTCOME FATIGUE (MULTIDIMENSIONAL FATIGUE INVENTORY [MFI]; GENERAL FATIGUE) AND SECONDARY OUTCOMES FATIGUE (MFI, FATIGUE QUALITY LIST [FQL]), QUALITY OF LIFE (30-ITEM QUALITY OF LIFE QUESTIONNAIRE-C OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER [EORTC-QLQ-C-30]) AND PSYCHOLOGICAL DISTRESS (HOSPITAL ANXIETY DEPRESSION SCALE [HADS], IMPACT OF EVENTS SCALE [IES]) WERE MEASURED AT BASELINE (T0), 3 MONTHS (T1), AND 6 MONTHS (T2) AND ANALYZED ON OBSERVED CASES. OTHER OUTCOMES WERE ADEQUATE RELIEF, REINTEGRATION TO WORK, AND ADVERSE EVENTS. RESULTS: NO SIGNIFICANT DIFFERENCES WERE FOUND IN GENERAL FATIGUE AT T1 (MFI: YOGA; 14.6 +/- 4.5 VS. SC; 14.2 +/- 4.2, P = 0.987). SIMILAR FINDINGS WERE OBSERVED FOR OTHER FATIGUE (SUB)SCALES OF MFI AND FQL AND FUNCTIONAL DOMAINS OF EORTC. WITH RESPECT TO EORTCS SYMPTOM SCALES, WOMEN IN THE YOGA GROUP REPORTED SIGNIFICANTLY LESS NAUSEA AND VOMITING COMPARED WITH SC AT T2 (P = 0.004), BUT NOT AT T1 (P = 0.807). DEPRESSIVE SYMPTOMS WERE SIGNIFICANTLY LOWER WITH YOGA AT T1 (HADS: YOGA; 4.7 +/- 4.1 VS. SC; 5.1 +/- 4.2, P = 0.031). MORE WOMEN IN THE YOGA GROUP EXPERIENCED ADEQUATE RELIEF COMPARED WITH SC AT T1 (YOGA; 51% VS. SC; 19%) AND HAD RETURNED TO WORK AT T2 (YOGA; 53% VS. SC; 23%). NO ADVERSE EVENTS WERE REPORTED WITH YOGA. CONCLUSIONS: A DRU-BASED YOGA PROGRAM FAILED TO DEMONSTRATE A SIGNIFICANT BENEFICIAL EFFECT ON FATIGUE. POSSIBLE FAVORABLE EFFECTS OF THE YOGA PROGRAM ON NAUSEA AND VOMITING AND EARLY RETURN TO WORK IN BREAST CANCER SURVIVORS WARRANT FURTHER RESEARCH. 2018 2 2529 44 YOGA EFFECTIVELY REDUCES FATIGUE AND SYMPTOMS OF DEPRESSION IN PATIENTS WITH DIFFERENT TYPES OF CANCER. PURPOSE: EXAMINE THE EFFECTS OF AN 8-WEEK YOGA THERAPY ON FATIGUE IN PATIENTS WITH DIFFERENT TYPES OF CANCER. METHODS: A TOTAL OF 173 CANCER PATIENTS SUFFERING FROM MILD TO SEVERE FATIGUE WERE RANDOMLY ALLOCATED TO YOGA INTERVENTION (N = 84) (IG) VERSUS WAITLIST CONTROL GROUP (CG) (N = 88). YOGA THERAPY CONSISTED OF EIGHT WEEKLY SESSIONS WITH 60 MIN EACH. THE PRIMARY OUTCOME WAS SELF-REPORTED FATIGUE SYMPTOMS. SECONDARY OUTCOMES WERE SYMPTOMS OF DEPRESSION AND QUALITY OF LIFE (QOL). DATA WERE ASSESSED USING QUESTIONNAIRES BEFORE (T0) AND AFTER YOGA THERAPY FOR IG VERSUS WAITING PERIOD FOR CG (T1). RESULTS: A STRONGER REDUCTION OF GENERAL FATIGUE (P = .033), PHYSICAL FATIGUE (P = .048), AND DEPRESSION (P < .001) AS WELL AS A STRONGER INCREASE IN QOL (P = .002) WAS FOUND FOR PATIENTS WHO ATTENDED 7 OR 8 SESSIONS COMPARED WITH CONTROLS. WITHIN THE YOGA GROUP, BOTH HIGHER ATTENDANCE RATE AND LOWER T0-FATIGUE WERE SIGNIFICANT PREDICTORS OF LOWER T1-FATIGUE (P .05) OR ANXIETY (F = 2.7, P > .05). CONCLUSIONS/IMPLICATIONS FOR PRACTICE: THE 8-WEEK YOGA EXERCISE PROGRAM DEVELOPED IN THIS STUDY EFFECTIVELY REDUCED FATIGUE IN PATIENTS WITH BREAST CANCER BUT DID NOT REDUCE DEPRESSION OR ANXIETY. ONCOLOGY NURSES SHOULD STRENGTHEN THEIR CLINICAL HEALTH EDUCATION AND APPLY YOGA TO REDUCE THE FATIGUE EXPERIENCED BY PATIENTS WITH BREAST CANCER WHO UNDERGO ADJUVANT CHEMOTHERAPY. 2014 4 1534 53 IYENGAR-YOGA COMPARED TO EXERCISE AS A THERAPEUTIC INTERVENTION DURING (NEO)ADJUVANT THERAPY IN WOMEN WITH STAGE I-III BREAST CANCER: HEALTH-RELATED QUALITY OF LIFE, MINDFULNESS, SPIRITUALITY, LIFE SATISFACTION, AND CANCER-RELATED FATIGUE. THIS STUDY AIMS TO TEST THE EFFECTS OF YOGA ON HEALTH-RELATED QUALITY OF LIFE, LIFE SATISFACTION, CANCER-RELATED FATIGUE, MINDFULNESS, AND SPIRITUALITY COMPARED TO CONVENTIONAL THERAPEUTIC EXERCISES DURING (NEO)ADJUVANT CYTOTOXIC AND ENDOCRINE THERAPY IN WOMEN WITH BREAST CANCER. IN A RANDOMIZED CONTROLLED TRIAL 92 WOMEN WITH BREAST CANCER UNDERGOING ONCOLOGICAL TREATMENT WERE RANDOMLY ENROLLED FOR A YOGA INTERVENTION (YI) (N = 45) OR FOR A PHYSICAL EXERCISE INTERVENTION (PEI) (N = 47). MEASUREMENTS WERE OBTAINED BEFORE (T 0) AND AFTER THE INTERVENTION (T 1) AS WELL AS 3 MONTHS AFTER FINISHING INTERVENTION (T 2) USING STANDARDIZED QUESTIONNAIRES. LIFE SATISFACTION AND FATIGUE IMPROVED UNDER PEI (P < 0.05) BUT NOT UNDER YI (T 0 TO T 2). REGARDING QUALITY OF LIFE (EORTC QLQ-C30) A DIRECT EFFECT (T 0 TO T 1; P < 0.001) OF YI WAS FOUND ON ROLE AND EMOTIONAL FUNCTIONING, WHILE UNDER PEI ONLY EMOTIONAL FUNCTIONING IMPROVED. SIGNIFICANT IMPROVEMENTS (P < 0.001) WERE OBSERVED AT BOTH T 1 AND T 2 ALSO FOR SYMPTOM SCALES IN BOTH GROUPS: DYSPNEA, APPETITE LOSS, CONSTIPATION, AND DIARRHEA. THERE WAS NO SIGNIFICANT DIFFERENCE BETWEEN THERAPIES FOR NONE OF THE ANALYZED VARIABLES NEITHER FOR T 1 NOR FOR T 2. DURING CHEMOTHERAPY, YOGA WAS NOT SEEN AS MORE HELPFUL THAN CONVENTIONAL THERAPEUTIC EXERCISES. THIS DOES NOT ARGUE AGAINST ITS USE IN THE RECOVERY PHASE. 2016 5 1245 46 FEASIBILITY OF IMPLEMENTING A COMMUNITY-BASED RANDOMIZED TRIAL OF YOGA FOR WOMEN UNDERGOING CHEMOTHERAPY FOR BREAST CANCER. BACKGROUND: TREATMENT-RELATED SYMPTOMS AND DECREASED HEALTH-RELATED QUALITY OF LIFE (HRQOL) FREQUENTLY OCCUR DURING CHEMOTHERAPY FOR BREAST CANCER. ALTHOUGH RESEARCH FINDINGS SUGGEST THAT YOGA CAN REDUCE SYMPTOMS AND IMPROVE HRQOL AFTER TREATMENT, POTENTIAL BENEFITS OF YOGA DURING CHEMOTHERAPY HAVE RECEIVED MINIMAL ATTENTION. OBJECTIVE: TO ESTIMATE ACCRUAL, ADHERENCE, STUDY RETENTION, AND PRELIMINARY EFFICACY OF A YOGA INTERVENTION COMPARED WITH AN ACTIVE CONTROL GROUP FOR BREAST CANCER PATIENTS DURING CHEMOTHERAPY. METHODS: WOMEN WITH STAGE I-III BREAST CANCER WERE RECRUITED FROM 3 COMMUNITY CANCER CLINICS AND RANDOMIZED TO 10 WEEKS OF GENTLE YOGA OR WELLNESS EDUCATION. DEPRESSIVE SYMPTOMS, FATIGUE, SLEEP, AND HRQOL WERE ASSESSED AT BASELINE, MID-INTERVENTION (WEEK 5), AND AFTER INTERVENTION (WEEK 10). RESULTS: 40 WOMEN AGED 29-83 YEARS (MEDIAN, 48 YEARS; 88% WHITE) WERE RANDOMIZED TO YOGA (N = 22) OR WELLNESS EDUCATION (N = 18). THE GROUPS DID NOT DIFFER SIGNIFICANTLY ON BASELINE CHARACTERISTICS, ADHERENCE, OR STUDY RETENTION. PARTICIPANT FEEDBACK WAS POSITIVE AND COMPARABLE BETWEEN GROUPS. MEANINGFUL WITHIN-GROUP DIFFERENCES WERE IDENTIFIED FOR SLEEP ADEQUACY AND QUANTITY IN YOGA PARTICIPANTS AND FOR SOMNOLENCE IN WELLNESS-EDUCATION PARTICIPANTS. LIMITATIONS: SMALL SAMPLE SIZE AND LACK OF A USUAL-CARE CONTROL GROUP. CONCLUSIONS: THIS STUDY ESTABLISHED FEASIBILITY OF A COMMUNITY-BASED RANDOMIZED TRIAL OF YOGA AND AN ACTIVE COMPARISON GROUP FOR WOMEN UNDERGOING CHEMOTHERAPY FOR BREAST CANCER. PRELIMINARY EFFICACY ESTIMATES SUGGEST THAT YOGA IMPROVES SLEEP ADEQUACY SYMPTOM SEVERITY AND INTERFERENCE REMAINED STABLE DURING CHEMOTHERAPY FOR THE YOGA GROUP AND SNOWED A TREND TOWARD INCREASING IN THE CONTROL GROUP. THE STUDY HIGHLIGHTED OBSTACLES TO MULTISITE YOGA RESEARCH DURING CANCER TREATMENT. FUNDING/SPONSORSHIP: NATIONAL CANCER INSTITUTE (3U10 CA081851, PI; SHAW; R25 CA122061, PI: AVIS); TRANSLATIONAL SCIENCE INSTITUTE, WAKE FOREST SCHOOL OF MEDICINE. 2015 6 1585 42 MEDICAL YOGA FOR PATIENTS WITH STRESS-RELATED SYMPTOMS AND DIAGNOSES IN PRIMARY HEALTH CARE: A RANDOMIZED CONTROLLED TRIAL. AN INCREASING NUMBER OF PATIENTS ARE SUFFERING FROM STRESS-RELATED SYMPTOMS AND DIAGNOSES. THE PURPOSE OF THIS STUDY WAS TO EVALUATE THE MEDICAL YOGA TREATMENT IN PATIENTS WITH STRESS-RELATED SYMPTOMS AND DIAGNOSES IN PRIMARY HEALTH CARE. A RANDOMIZED CONTROLLED STUDY WAS PERFORMED AT A PRIMARY HEALTH CARE CENTRE IN SWEDEN FROM MARCH TO JUNE, 2011. PATIENTS WERE RANDOMLY ALLOCATED TO A CONTROL GROUP RECEIVING STANDARD CARE OR A YOGA GROUP TREATED WITH MEDICAL YOGA FOR 1 HOUR, ONCE A WEEK, OVER A 12-WEEK PERIOD IN ADDITION TO THE STANDARD CARE. A TOTAL OF 37 MEN AND WOMEN, MEAN AGE OF 53 +/- 12 YEARS WERE INCLUDED. GENERAL STRESS LEVEL (MEASURED USING PERCEIVED STRESS SCALE (PSS)), BURNOUT (SHIROM-MELAMED BURNOUT QUESTIONNAIRE (SMBQ)), ANXIETY AND DEPRESSION (HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS)), INSOMNIA SEVERITY (INSOMNIA SEVERITY INDEX (ISI)), PAIN (VISUAL ANALOGUE SCALE (VAS)), AND OVERALL HEALTH STATUS (EURO QUALITY OF LIFE VAS (EQ-VAS)) WERE MEASURED BEFORE AND AFTER 12 WEEKS. PATIENTS ASSIGNED TO THE YOGA GROUP SHOWED SIGNIFICANTLY GREATER IMPROVEMENTS ON MEASURES OF GENERAL STRESS LEVEL (P < 0.000), ANXIETY (P < 0.019), AND OVERALL HEALTH STATUS (P < 0.018) COMPARED TO CONTROLS. TREATMENT WITH MEDICAL YOGA IS EFFECTIVE IN REDUCING LEVELS OF STRESS AND ANXIETY IN PATIENTS WITH STRESS-RELATED SYMPTOMS IN PRIMARY HEALTH CARE. 2013 7 2896 32 [EFFECT OF YOGA ON CANCER RELATED FATIGUE IN BREAST CANCER PATIENTS WITH CHEMOTHERAPY]. OBJECTIVE: TO EVALUATE THE CONDITION OF CANCER-RELATED FATIGUE (CRF) IN BREAST CANCER PATIENTS WITH CHEMOTHERAPY AND TO EXPLORE THE EFFECT OF YOGA ON IT. METHODS: AFTER THE COMPLETION OF YOGA, 100 BREAST CANCER PATIENTS WITH CRF (CFS>0) WERE SELECTED AND WERE RANDOMLY DIVIDED INTO THE YOGA GROUP AND THE CONTROL GROUP (N=50). PATIENTS IN THE CONTROL GROUP ONLY RECEIVED ROUTINE CURE AND CARE WHILE PATIENTS IN THE YOGA GROUP RECEIVED EXTRA YOGA EXERCISE, LASTING FOR 4 MONTHS. CANCER FATIGUE SCALE (CFS) WAS EVALUATED IN THE 2ND, 4TH AND 6TH ROUND OF CHEMOTHERAPY. RESULTS: AT THE END, 82 CASES QUALIFIED FOR THE STUDY, 42 CASES FOR THE CONTROL GROUP AND 40 FOR THE YOGA GROUP. THE MEAN SCORE OF BODY FATIGUE WAS 12.67+/-3.46. THERE WAS NO SIGNIFICANT DIFFERENCE IN CRF BETWEEN THE YAGO GROUP AND THE CONTROL GROUP BEFORE THE YOGA INTERVENTION (P>0.05). AFTER THE 4TH ROUND OF CHEMOTHERAPY, THE MEAN SCORES OF CFS AND BODY FATIGUE IN THE YOGA GROUP WERE SIGNIFICANTLY LOWER THAN THAT IN THE CONTROL GROUP (P<0.05). AFTER THE 6TH ROUND OF CHEMOTHERAPY, THE MEAN SCORES OF CFS, BODY FATIGUE AND COGNITIVE FATIGUE IN THE YOGA GROUP WERE LOWER THAN THAT IN THE CONTROL GROUP (P<0.05). REPEATED ANALYSIS OF VARIANCE SHOWED THAT THE DIFFERENCE IN THE OVERALL FATIGUE, BODY FATIGUE AND COGNITIVE FATIGUE BETWEEN THE YOGA GROUP AND THE CONTROL GROUP WAS SIGNIFICANT (P<0.05); THE TIME INFLUENCE ON THE OVERALL FATIGUE, BODY FATIGUE AND EMOTIONAL FATIGUE WAS SIGNIFICANT DIFFERENCE BETWEEN THE 2 GROUPS (P<0.05); THERE WERE INTERACTIONS BETWEEN THE EFFECT OF YAGO AND TIME ON THE OVERALL FATIGUE, BODY FATIGUE AND COGNITIVE FATIGUE (P<0.05). CONCLUSION: THE BODY FATIGUE WAS MORE SERIOUS IN BREAST CANCER PATIENTS WITH CHEMOTHERAPY. YOGA INTERVENTION COULD SIGNIFICANTLY REDUCE BODY FATIGUE, COGNITIVE FATIGUE, THUS REDUCE THE OVERALL FATIGUE IN BREAST CANCER PATIENTS WITH CHEMOTHERAPY. 2014 8 2604 45 YOGA FOR PERSISTENT FATIGUE IN BREAST CANCER SURVIVORS: A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: CANCER-RELATED FATIGUE AFFLICTS UP TO 33% OF BREAST CANCER SURVIVORS, YET THERE ARE NO EMPIRICALLY VALIDATED TREATMENTS FOR THIS SYMPTOM. METHODS: THE AUTHORS CONDUCTED A 2-GROUP RANDOMIZED CONTROLLED TRIAL TO DETERMINE THE FEASIBILITY AND EFFICACY OF AN IYENGAR YOGA INTERVENTION FOR BREAST CANCER SURVIVORS WITH PERSISTENT POST-TREATMENT FATIGUE. PARTICIPANTS WERE BREAST CANCER SURVIVORS WHO HAD COMPLETED CANCER TREATMENTS (OTHER THAN ENDOCRINE THERAPY) AT LEAST 6 MONTHS BEFORE ENROLLMENT, REPORTED SIGNIFICANT CANCER-RELATED FATIGUE, AND HAD NO OTHER MEDICAL CONDITIONS THAT WOULD ACCOUNT FOR FATIGUE SYMPTOMS OR INTERFERE WITH YOGA PRACTICE. BLOCK RANDOMIZATION WAS USED TO ASSIGN PARTICIPANTS TO A 12-WEEK, IYENGAR-BASED YOGA INTERVENTION OR TO 12 WEEKS OF HEALTH EDUCATION (CONTROL). THE PRIMARY OUTCOME WAS CHANGE IN FATIGUE MEASURED AT BASELINE, IMMEDIATELY POST-TREATMENT, AND 3 MONTHS AFTER TREATMENT COMPLETION. ADDITIONAL OUTCOMES INCLUDED CHANGES IN VIGOR, DEPRESSIVE SYMPTOMS, SLEEP, PERCEIVED STRESS, AND PHYSICAL PERFORMANCE. INTENT-TO-TREAT ANALYSES WERE CONDUCTED WITH ALL RANDOMIZED PARTICIPANTS USING LINEAR MIXED MODELS. RESULTS: THIRTY-ONE WOMEN WERE RANDOMLY ASSIGNED TO YOGA (N = 16) OR HEALTH EDUCATION (N = 15). FATIGUE SEVERITY DECLINED SIGNIFICANTLY FROM BASELINE TO POST-TREATMENT AND OVER A 3-MONTH FOLLOW-UP IN THE YOGA GROUP RELATIVE TO CONTROLS (P = .032). IN ADDITION, THE YOGA GROUP HAD SIGNIFICANT INCREASES IN VIGOR RELATIVE TO CONTROLS (P = .011). BOTH GROUPS HAD POSITIVE CHANGES IN DEPRESSIVE SYMPTOMS AND PERCEIVED STRESS (P < .05). NO SIGNIFICANT CHANGES IN SLEEP OR PHYSICAL PERFORMANCE WERE OBSERVED. CONCLUSIONS: A TARGETED YOGA INTERVENTION LED TO SIGNIFICANT IMPROVEMENTS IN FATIGUE AND VIGOR AMONG BREAST CANCER SURVIVORS WITH PERSISTENT FATIGUE SYMPTOMS. 2012 9 1087 54 EFFECTS OF YOGA ON SYMPTOM MANAGEMENT IN BREAST CANCER PATIENTS: A RANDOMIZED CONTROLLED TRIAL. OBJECTIVES: THIS STUDY COMPARES THE EFFECTS OF AN INTEGRATED YOGA PROGRAM WITH BRIEF SUPPORTIVE THERAPY ON DISTRESSFUL SYMPTOMS IN BREAST CANCER OUTPATIENTS UNDERGOING ADJUVANT RADIOTHERAPY. MATERIALS AND METHODS: EIGHTY-EIGHT STAGE II AND III BREAST CANCER OUTPATIENTS WERE RANDOMLY ASSIGNED TO RECEIVE YOGA (N = 44) OR BRIEF SUPPORTIVE THERAPY (N = 44) PRIOR TO THEIR RADIOTHERAPY TREATMENT. INTERVENTION CONSISTED OF YOGA SESSIONS LASTING 60 MIN DAILY WHILE THE CONTROL GROUP WAS IMPARTED SUPPORTIVE THERAPY ONCE IN 10 DAYS DURING THE COURSE OF THEIR ADJUVANT RADIOTHERAPY. ASSESSMENTS INCLUDED ROTTERDAM SYMPTOM CHECK LIST AND EUROPEAN ORGANIZATION FOR RESEARCH IN THE TREATMENT OF CANCER-QUALITY OF LIFE (EORTC QOL C30) SYMPTOM SCALE. ASSESSMENTS WERE DONE AT BASELINE AND AFTER 6 WEEKS OF RADIOTHERAPY TREATMENT. RESULTS: A GLM REPEATED-MEASURES ANOVA SHOWED A SIGNIFICANT DECREASE IN PSYCHOLOGICAL DISTRESS (P = 0.01), FATIGUE (P = 0.007), INSOMNIA (P = 0.001), AND APPETITE LOSS (P = 0.002) OVER TIME IN THE YOGA GROUP AS COMPARED TO CONTROLS. THERE WAS SIGNIFICANT IMPROVEMENT IN THE ACTIVITY LEVEL (P = 0.02) IN THE YOGA GROUP AS COMPARED TO CONTROLS. THERE WAS A SIGNIFICANT POSITIVE CORRELATION BETWEEN PHYSICAL AND PSYCHOLOGICAL DISTRESS AND FATIGUE, NAUSEA AND VOMITING, PAIN, DYSPNEA, INSOMNIA, APPETITE LOSS, AND CONSTIPATION. THERE WAS A SIGNIFICANT NEGATIVE CORRELATION BETWEEN THE ACTIVITY LEVEL AND FATIGUE, NAUSEA AND VOMITING, PAIN, DYSPNEA, INSOMNIA, AND APPETITE LOSS. CONCLUSION: THE RESULTS SUGGEST BENEFICIAL EFFECTS WITH YOGA INTERVENTION IN MANAGING CANCER-AND TREATMENT-RELATED SYMPTOMS IN BREAST CANCER PATIENTS. 2009 10 1232 49 FEASIBILITY AND POTENTIAL BENEFITS OF PARTNER-SUPPORTED YOGA ON PSYCHOSOCIAL AND PHYSICAL FUNCTION AMONG LUNG CANCER PATIENTS. OBJECTIVE: PATIENTS WITH LUNG CANCER EXPERIENCE SIGNIFICANT DECLINES IN PSYCHOSOCIAL AND PHYSICAL FUNCTION DURING AND AFTER TREATMENT THAT IMPACT QUALITY OF LIFE (QOL) AND SURVIVAL. YOGA IS A POTENTIAL STRATEGY TO MITIGATE FUNCTIONAL DECLINE AMONG PATIENTS WITH LUNG CANCER. METHODS: A SINGLE GROUP 12-WEEK PILOT TRIAL OF LOW-MODERATE INTENSITY YOGA AMONG PATIENTS WITH STAGE I-IV LUNG CANCER AND THEIR PARTNERS (N = 46; 23 PATIENT-PARTNER DYADS) DURING CANCER TREATMENT FROM TWO HOSPITAL SYSTEMS. FEASIBILITY, ACCEPTABILITY, DESCRIPTIVE STATISTICS, AND COHEN D EFFECT SIZES WERE CALCULATED AT 6 AND 12-WEEKS FOR PSYCHOSOCIAL AND PHYSICAL OUTCOMES USING VALIDATED QUESTIONNAIRES AND ASSESSMENTS. RESULTS: AT 6 AND 12-WEEKS, RETENTION WAS 65% AND WITHDRAWALS WERE MAINLY DUE TO DISEASE PROGRESSION. AMONG STUDY COMPLETERS (N = 26; 13 DYADS) ADHERENCE WAS 80%. COMPARING BASELINE TO 12-WEEK MEASUREMENTS, FATIGUE, DEPRESSION SYMPTOMS, AND SLEEP DISTURBANCE IMPROVED IN 54% OF PARTICIPANTS FOR ALL THREE MEASURES (COHEN'S D = 0.40-0.53). QOL IMPROVED IN 77% OF PARTICIPANTS (COHEN'S D = 0.34). UPPER AND LOWER BODY FLEXIBILITY, AND LOWER BODY STRENGTH IMPROVED IN 92%, 85% AND 77% OF PARTICIPANTS, RESPECTIVELY (COHEN'S D = 0.39-1.08). SIX-MINUTE WALK TEST IMPROVED IN 62% OF PARTICIPANTS AN AVERAGE OF 32 METERS (SD = 11.3; COHEN'S D = 0.17). NO SERIOUS ADVERSE EVENTS WERE REPORTED. CONCLUSIONS: AMONG PATIENTS WITH STAGE I-IV LUNG CANCER INCLUDING ACTIVE TREATMENT, A 12-WEEK PARTNER-SUPPORTED YOGA PROGRAM IS FEASIBLE, ACCEPTABLE, AND IMPROVED PSYCHOSOCIAL AND PHYSICAL FUNCTION. LOW-INTENSITY YOGA MAY BE A COMPLIMENTARY APPROACH TO REDUCE THE EFFECTS OF CANCER TREATMENT, HOWEVER, MORE RESEARCH IS NEEDED TO DETERMINE THE EFFICACY OF PARTNER-SUPPORTED YOGA TO MITIGATE FUNCTIONAL DECLINE. 2021 11 1863 46 RANDOMIZED CONTROLLED TRIAL OF YOGA AND EXERCISE IN MULTIPLE SCLEROSIS. OBJECTIVE: TO DETERMINE THE EFFECT OF YOGA AND OF AEROBIC EXERCISE ON COGNITIVE FUNCTION, FATIGUE, MOOD, AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS (MS). METHODS: SUBJECTS WITH CLINICALLY DEFINITE MS AND EXPANDED DISABILITY STATUS SCORE LESS THAN OR EQUAL TO 6.0 WERE RANDOMLY ASSIGNED TO ONE OF THREE GROUPS LASTING 6 MONTHS: WEEKLY IYENGAR YOGA CLASS ALONG WITH HOME PRACTICE, WEEKLY EXERCISE CLASS USING A STATIONARY BICYCLE ALONG WITH HOME EXERCISE, OR A WAITING-LIST CONTROL GROUP. OUTCOME ASSESSMENTS PERFORMED AT BASELINE AND AT THE END OF THE 6-MONTH PERIOD INCLUDED A BATTERY OF COGNITIVE MEASURES FOCUSED ON ATTENTION, PHYSIOLOGIC MEASURES OF ALERTNESS, PROFILE OF MOOD STATES, STATE-TRAIT ANXIETY INVENTORY, MULTI-DIMENSIONAL FATIGUE INVENTORY (MFI), AND SHORT FORM (SF)-36 HEALTH-RELATED QUALITY OF LIFE. RESULTS: SIXTY-NINE SUBJECTS WERE RECRUITED AND RANDOMIZED. TWELVE SUBJECTS DID NOT FINISH THE 6-MONTH INTERVENTION. THERE WERE NO ADVERSE EVENTS RELATED TO THE INTERVENTION. THERE WERE NO EFFECTS FROM EITHER OF THE ACTIVE INTERVENTIONS ON EITHER OF THE PRIMARY OUTCOME MEASURES OF ATTENTION OR ALERTNESS. BOTH ACTIVE INTERVENTIONS PRODUCED IMPROVEMENT IN SECONDARY MEASURES OF FATIGUE COMPARED TO THE CONTROL GROUP: ENERGY AND FATIGUE (VITALITY) ON THE SF-36 AND GENERAL FATIGUE ON THE MFI. THERE WERE NO CLEAR CHANGES IN MOOD RELATED TO YOGA OR EXERCISE. CONCLUSION: SUBJECTS WITH MS PARTICIPATING IN EITHER A 6-MONTH YOGA CLASS OR EXERCISE CLASS SHOWED SIGNIFICANT IMPROVEMENT IN MEASURES OF FATIGUE COMPARED TO A WAITING-LIST CONTROL GROUP. THERE WAS NO RELATIVE IMPROVEMENT OF COGNITIVE FUNCTION IN EITHER OF THE INTERVENTION GROUPS. 2004 12 206 32 A SELF-DIRECTED HOME YOGA PROGRAMME FOR WOMEN WITH BREAST CANCER DURING CHEMOTHERAPY: A FEASIBILITY STUDY. RECENT STUDIES SUGGEST YOGA AS A PROMISING APPROACH FOR IMPROVING THE COGNITIVE FUNCTION OF CANCER SURVIVORS. WE STUDIED WHETHER A SELF-DIRECTED HOME YOGA PROGRAMME WAS FEASIBLE FOR PATIENTS WITH BREAST CANCER WHO WERE UNDERGOING CHEMOTHERAPY. PARTICIPANTS' PREFERENCES FOR THE TYPE OF YOGA COURSE AND THE CLINICAL EFFECTS OF THE PROGRAMME WERE ALSO ASSESSED. IN THIS STUDY, 18 WOMEN (MEAN AGE, 43.9 YEARS) WERE ENROLLED (44.7% RECRUITMENT RATE). OF THE PARTICIPANTS, 63.6% HAD STAGE II CANCER AND 71.4% RECEIVED ADJUVANT CHEMOTHERAPY. FAVOURABLE RETENTION (86%), ADHERENCE (94.4%) AND ACCEPTABILITY (96.5%) RATES WERE DETERMINED. MOST (94.4%) OF THE WOMEN PRACTICED THE HOME PROGRAMME MORE THAN TWICE A WEEK ON AVERAGE. THE PARTICIPANTS PREFERRED TO GRADUALLY INCREASE THE INTENSITY OF THE EXERCISES. WE ONLY OBSERVED IMPROVEMENTS IN THE COGNITIVE ASPECTS OF FATIGUE. NO SERIOUS ADVERSE EVENTS WERE ENCOUNTERED DURING THE PROGRAMME. THIS SELF-DIRECTED HOME YOGA PROGRAMME WAS SAFE AND FEASIBLE FOR PATIENTS WITH BREAST CANCER UNDERGOING CHEMOTHERAPY. 2016 13 974 47 EFFECTS OF AN INTEGRATED YOGA PROGRAM ON SELF-REPORTED DEPRESSION SCORES IN BREAST CANCER PATIENTS UNDERGOING CONVENTIONAL TREATMENT: A RANDOMIZED CONTROLLED TRIAL. AIM: TO COMPARE THE EFFECTS OF YOGA PROGRAM WITH SUPPORTIVE THERAPY ON SELF-REPORTED SYMPTOMS OF DEPRESSION IN BREAST CANCER PATIENTS UNDERGOING CONVENTIONAL TREATMENT. PATIENTS AND METHODS: NINETY-EIGHT BREAST CANCER PATIENTS WITH STAGE II AND III DISEASE FROM A CANCER CENTER WERE RANDOMLY ASSIGNED TO RECEIVE YOGA (N = 45) AND SUPPORTIVE THERAPY (N = 53) OVER A 24-WEEK PERIOD DURING WHICH THEY UNDERWENT SURGERY FOLLOWED BY ADJUVANT RADIOTHERAPY (RT) OR CHEMOTHERAPY (CT) OR BOTH. THE STUDY STOPPAGE CRITERIA WAS PROGRESSIVE DISEASE RENDERING THE PATIENT BEDRIDDEN OR ANY PHYSICAL MUSCULOSKELETAL INJURY RESULTING FROM INTERVENTION OR LESS THAN 60% ATTENDANCE TO YOGA INTERVENTION. SUBJECTS UNDERWENT YOGA INTERVENTION FOR 60 MIN DAILY WITH CONTROL GROUP UNDERGOING SUPPORTIVE THERAPY DURING THEIR HOSPITAL VISITS. BECK'S DEPRESSION INVENTORY (BDI) AND SYMPTOM CHECKLIST WERE ASSESSED AT BASELINE, AFTER SURGERY, BEFORE, DURING, AND AFTER RT AND SIX CYCLES OF CT. WE USED ANALYSIS OF COVARIANCE (INTENT-TO-TREAT) TO STUDY THE EFFECTS OF INTERVENTION ON DEPRESSION SCORES AND PEARSON CORRELATION ANALYSES TO EVALUATE THE BIVARIATE RELATIONSHIPS. RESULTS: A TOTAL OF 69 PARTICIPANTS CONTRIBUTED DATA TO THE CURRENT ANALYSIS (YOGA, N = 33, AND CONTROLS, N = 36). THERE WAS 29% ATTRITION IN THIS STUDY. THE RESULTS SUGGEST AN OVERALL DECREASE IN SELF-REPORTED DEPRESSION WITH TIME IN BOTH THE GROUPS. THERE WAS A SIGNIFICANT DECREASE IN DEPRESSION SCORES IN THE YOGA GROUP AS COMPARED TO CONTROLS FOLLOWING SURGERY, RT, AND CT (P < 0.01). THERE WAS A POSITIVE CORRELATION (P < 0.001) BETWEEN DEPRESSION SCORES WITH SYMPTOM SEVERITY AND DISTRESS DURING SURGERY, RT, AND CT. CONCLUSION: THE RESULTS SUGGEST POSSIBLE ANTIDEPRESSANT EFFECTS WITH YOGA INTERVENTION IN BREAST CANCER PATIENTS UNDERGOING CONVENTIONAL TREATMENT. 2015 14 428 38 CAN YOGA HAVE ANY EFFECT ON SHOULDER AND ARM PAIN AND QUALITY OF LIFE IN PATIENTS WITH BREAST CANCER? A RANDOMIZED, CONTROLLED, SINGLE-BLIND TRIAL. OBJECTIVE: TO EXAMINE THE EFFECTS OF YOGA ON SHOULDER AND ARM PAIN, QUALITY OF LIFE (QOL), DEPRESSION, AND PHYSICAL PERFORMANCE IN PATIENTS WITH BREAST CANCER. METHODS: THIS PROSPECTIVE, RANDOMIZED STUDY INCLUDED 42 PATIENTS. THE PATIENTS IN GROUP 1 UNDERWENT A 10-WEEK HATHA YOGA EXERCISE PROGRAM. THE PATIENTS IN GROUP 2 WERE INCLUDED IN A 10-WEEK FOLLOW-UP PROGRAM. OUR PRIMARY ENDPOINT WAS ARM AND SHOULDER PAIN INTENSITY. RESULTS: THE GROUP RECEIVING YOGA SHOWED A SIGNIFICANT IMPROVEMENT IN THEIR PAIN SEVERITY FROM BASELINE TO POST-TREATMENT, AND THESE BENEFITS WERE MAINTAINED AT 2.5 MONTHS POST-TREATMENT. WHEN COMPARED TO THE CONTROL GROUP, THERE WERE NO STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN THE 2 GROUPS WITH RESPECT TO THE PARAMETERS ASSESSED AT THE END OF WEEK 10. CONCLUSION: YOGA WAS AN EFFECTIVE AND SAFE EXERCISE FOR ALLEVIATING SHOULDER AND ARM PAIN, WHICH IS A COMPLICATION WITH A HIGH PREVALENCE IN PATIENTS WITH BREAST CANCER. 2018 15 2549 48 YOGA FOR CANCER SURVIVORS WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: HEALTH-RELATED QUALITY OF LIFE OUTCOMES. BACKGROUND: YOGA IS A MEDITATIVE MOVEMENT THERAPY FOCUSED ON MIND-BODY AWARENESS. THE IMPACT OF YOGA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES IN PATIENTS WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) IS UNCLEAR. METHODS: WE CONDUCTED A PILOT RANDOMIZED WAIT-LIST CONTROLLED TRIAL OF 8 WEEKS OF YOGA (N = 21) VERSUS WAIT-LIST CONTROL (N = 20) FOR CIPN IN 41 BREAST AND GYNECOLOGICAL CANCER SURVIVORS WITH PERSISTENT MODERATE TO SEVERE CIPN. HRQOL ENDPOINTS WERE HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS), BRIEF FATIGUE INVENTORY (BFI), AND INSOMNIA SEVERITY INDEX (ISI). THE TREATMENT EXPECTANCY SCALE (TES) WAS ADMINISTERED AT BASELINE. WE ESTIMATED MEAN CHANGES AND 95% CONFIDENCE INTERVALS (CIS) FROM BASELINE TO WEEKS 8 AND 12 AND COMPARED ARMS USING CONSTRAINED LINEAR MIXED MODELS. RESULTS: AT WEEK 8, HADS ANXIETY SCORES DECREASED -1.61 (-2.75, -0.46) IN THE YOGA ARM AND -0.32 (-1.38, 0.75) POINTS IN THE WAIT-LIST CONTROL ARM (P = 0.099). AT WEEK 12, HADS ANXIETY SCORES DECREASED -1.42 (-2.57, -0.28) IN YOGA COMPARED TO AN INCREASE OF 0.46 (-0.60, 1.53) IN WAIT-LIST CONTROL (P = 0.017). THERE WERE NO SIGNIFICANT DIFFERENCES IN HADS DEPRESSION, BFI, OR ISI SCORES BETWEEN YOGA AND WAIT-LIST CONTROL. BASELINE TES WAS SIGNIFICANTLY HIGHER IN YOGA THAN IN WAIT-LIST CONTROL (14.9 VS. 12.7, P = 0.019). TES WAS NOT ASSOCIATED WITH HADS ANXIETY REDUCTION AND HADS ANXIETY REDUCTION WAS NOT ASSOCIATED WITH CIPN PAIN REDUCTION. CONCLUSIONS: YOGA MAY REDUCE ANXIETY IN PATIENTS WITH CIPN. FUTURE STUDIES ARE NEEDED TO CONFIRM THESE FINDINGS. CLINICAL TRIAL REGISTRATION NUMBER: CLINICALTRIALS.GOV IDENTIFIER: NCT03292328. 2021 16 1036 34 EFFECTS OF YOGA IN MANAGING FATIGUE IN BREAST CANCER PATIENTS: A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: CANCER-RELATED FATIGUE IS WIDELY PREVALENT IN CANCER PATIENTS AND AFFECTS QUALITY OF LIFE IN ADVANCED CANCER PATIENTS. FATIGUE IS CAUSED DUE TO BOTH PSYCHOLOGIC DISTRESS AND PHYSIOLOGICAL SEQUEL FOLLOWING CANCER PROGRESSION AND ITS TREATMENT. IN THIS STUDY, WE EVALUATE THE EFFECTS OF YOGIC INTERVENTION IN MANAGING FATIGUE IN METASTATIC BREAST CANCER PATIENTS. METHODS: NINETY-ONE PATIENTS WITH METASTATIC BREAST CANCER WERE RANDOMIZED TO RECEIVE INTEGRATED YOGA PROGRAM (N = 46) OR SUPPORTIVE THERAPY AND EDUCATION (N = 45) OVER A 3-MONTH PERIOD. ASSESSMENTS SUCH AS PERCEIVED STRESS, FATIGUE SYMPTOM INVENTORY, DIURNAL SALIVARY CORTISOL, AND NATURAL KILLER CELL COUNTS WERE CARRIED OUT BEFORE AND AFTER INTERVENTION. ANALYSIS WAS DONE USING AN INTENTION-TO-TREAT APPROACH. POSTMEASURES FOR THE ABOVE OUTCOMES WERE ASSESSED USING ANCOVA WITH RESPECTIVE BASELINE MEASURE AS A COVARIATE. RESULTS: THE RESULTS SUGGEST THAT YOGA REDUCES PERCEIVED STRESS (P = 0.001), FATIGUE FREQUENCY (P < 0.001), FATIGUE SEVERITY (P < 0.001), INTERFERENCE (P < 0.001), AND DIURNAL VARIATION (P < 0.001) WHEN COMPARED TO SUPPORTIVE THERAPY. THERE WAS A POSITIVE CORRELATION OF CHANGE IN FATIGUE SEVERITY WITH 9 A.M. SALIVARY CORTISOL LEVELS. CONCLUSION: THE RESULTS SUGGEST THAT YOGA REDUCES FATIGUE IN ADVANCED BREAST CANCER PATIENTS. 2017 17 290 42 ADJUNCTIVE YOGA V. HEALTH EDUCATION FOR PERSISTENT MAJOR DEPRESSION: A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: THE OBJECTIVE OF THIS STUDY WAS TO DETERMINE WHETHER HATHA YOGA IS AN EFFICACIOUS ADJUNCTIVE INTERVENTION FOR INDIVIDUALS WITH CONTINUED DEPRESSIVE SYMPTOMS DESPITE ANTIDEPRESSANT TREATMENT. METHOD: WE CONDUCTED A RANDOMIZED CONTROLLED TRIAL OF WEEKLY YOGA CLASSES (N = 63) V. HEALTH EDUCATION CLASSES (HEALTHY LIVING WORKSHOP; HLW; N = 59) IN INDIVIDUALS WITH ELEVATED DEPRESSION SYMPTOMS AND ANTIDEPRESSANT MEDICATION USE. HLW SERVED AS AN ATTENTION-CONTROL GROUP. THE INTERVENTION PERIOD WAS 10 WEEKS, WITH FOLLOW-UP ASSESSMENTS 3 AND 6 MONTHS AFTERWARDS. THE PRIMARY OUTCOME WAS DEPRESSION SYMPTOM SEVERITY ASSESSED BY BLIND RATER AT 10 WEEKS. SECONDARY OUTCOMES INCLUDED DEPRESSION SYMPTOMS OVER THE ENTIRE INTERVENTION AND FOLLOW-UP PERIODS, SOCIAL AND ROLE FUNCTIONING, GENERAL HEALTH PERCEPTIONS, PAIN, AND PHYSICAL FUNCTIONING. RESULTS: AT 10 WEEKS, WE DID NOT FIND A STATISTICALLY SIGNIFICANT DIFFERENCE BETWEEN GROUPS IN DEPRESSION SYMPTOMS (B = -0.82, S.E. = 0.88, P = 0.36). HOWEVER, OVER THE ENTIRE INTERVENTION AND FOLLOW-UP PERIOD, WHEN CONTROLLING FOR BASELINE, YOGA PARTICIPANTS SHOWED LOWER LEVELS OF DEPRESSION THAN HLW PARTICIPANTS (B = -1.38, S.E. = 0.57, P = 0.02). AT 6-MONTH FOLLOW-UP, 51% OF YOGA PARTICIPANTS DEMONSTRATED A RESPONSE (50% REDUCTION IN DEPRESSION SYMPTOMS) COMPARED WITH 31% OF HLW PARTICIPANTS (ODDS RATIO = 2.31; P = 0.04). YOGA PARTICIPANTS SHOWED SIGNIFICANTLY BETTER SOCIAL AND ROLE FUNCTIONING AND GENERAL HEALTH PERCEPTIONS OVER TIME. CONCLUSIONS: ALTHOUGH WE DID NOT SEE A DIFFERENCE IN DEPRESSION SYMPTOMS AT THE END OF THE INTERVENTION PERIOD, YOGA PARTICIPANTS SHOWED FEWER DEPRESSION SYMPTOMS OVER THE ENTIRE FOLLOW-UP PERIOD. BENEFITS OF YOGA MAY ACCUMULATE OVER TIME. 2017 18 1825 49 PSYCHOLOGICAL ADJUSTMENT AND SLEEP QUALITY IN A RANDOMIZED TRIAL OF THE EFFECTS OF A TIBETAN YOGA INTERVENTION IN PATIENTS WITH LYMPHOMA. BACKGROUND: RESEARCH SUGGESTS THAT STRESS-REDUCTION PROGRAMS TAILORED TO THE CANCER SETTING HELP PATIENTS COPE WITH THE EFFECTS OF TREATMENT AND IMPROVE THEIR QUALITY OF LIFE. YOGA, AN ANCIENT EASTERN SCIENCE, INCORPORATES STRESS-REDUCTION TECHNIQUES THAT INCLUDE REGULATED BREATHING, VISUAL IMAGERY, AND MEDITATION AS WELL AS VARIOUS POSTURES. THE AUTHORS EXAMINED THE EFFECTS OF THE TIBETAN YOGA (TY) PRACTICES OF TSA LUNG AND TRUL KHOR, WHICH INCORPORATE CONTROLLED BREATHING AND VISUALIZATION, MINDFULNESS TECHNIQUES, AND LOW-IMPACT POSTURES IN PATIENTS WITH LYMPHOMA. METHODS: THIRTY-NINE PATIENTS WITH LYMPHOMA WHO WERE UNDERGOING TREATMENT OR WHO HAD CONCLUDED TREATMENT WITHIN THE PAST 12 MONTHS WERE ASSIGNED TO A TY GROUP OR TO A WAIT-LIST CONTROL GROUP. PATIENTS IN THE TY GROUP PARTICIPATED IN 7 WEEKLY YOGA SESSIONS, AND PATIENTS IN THE WAIT-LIST CONTROL GROUP WERE FREE TO PARTICIPATE IN THE TY PROGRAM AFTER THE 3-MONTH FOLLOW-UP ASSESSMENT. RESULTS: EIGHTY NINE PERCENT OF TY PARTICIPANTS COMPLETED AT LEAST 2-3 THREE YOGA SESSIONS, AND 58% COMPLETED AT LEAST 5 SESSIONS. PATIENTS IN THE TY GROUP REPORTED SIGNIFICANTLY LOWER SLEEP DISTURBANCE SCORES DURING FOLLOW-UP COMPARED WITH PATIENTS IN THE WAIT-LIST CONTROL GROUP (5.8 VS. 8.1; P < 0.004). THIS INCLUDED BETTER SUBJECTIVE SLEEP QUALITY (P < 0.02), FASTER SLEEP LATENCY (P < 0.01), LONGER SLEEP DURATION (P < 0.03), AND LESS USE OF SLEEP MEDICATIONS (P < 0.02). THERE WERE NO SIGNIFICANT DIFFERENCES BETWEEN GROUPS IN TERMS OF INTRUSION OR AVOIDANCE, STATE ANXIETY, DEPRESSION, OR FATIGUE. CONCLUSIONS: THE PARTICIPATION RATES SUGGESTED THAT A TY PROGRAM IS FEASIBLE FOR PATIENTS WITH CANCER AND THAT SUCH A PROGRAM SIGNIFICANTLY IMPROVES SLEEP-RELATED OUTCOMES. HOWEVER, THERE WERE NO SIGNIFICANT DIFFERENCES BETWEEN GROUPS FOR THE OTHER OUTCOMES. 2004 19 2415 64 YOGA AND MEDITATION FOR MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS-A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: BREAST CANCER SURVIVORS HAVE ONLY VERY LIMITED TREATMENT OPTIONS FOR MENOPAUSAL SYMPTOMS. THE OBJECTIVE OF THIS TRIAL WAS TO EVALUATE THE EFFECTS OF A 12-WEEK TRADITIONAL HATHA YOGA AND MEDITATION INTERVENTION ON MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS. METHODS: PATIENTS WERE RANDOMLY ASSIGNED EITHER TO A 12-WEEK YOGA AND MEDITATION INTERVENTION OR TO USUAL CARE. THE PRIMARY OUTCOME MEASURE WAS TOTAL MENOPAUSAL SYMPTOMS (MENOPAUSE RATING SCALE [MRS] TOTAL SCORE). SECONDARY OUTCOME MEASURES INCLUDED MRS SUBSCALES, QUALITY OF LIFE (FUNCTIONAL ASSESSMENT OF CANCER THERAPY-BREAST), FATIGUE (FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE), DEPRESSION, AND ANXIETY (HOSPITAL ANXIETY AND DEPRESSION SCALE). OUTCOMES WERE ASSESSED AT WEEK 12 AND WEEK 24 AFTER RANDOMIZATION. RESULTS: IN TOTAL, 40 WOMEN (MEAN AGE +/- STANDARD DEVIATION, 49.2 +/- 5.9 YEARS) WERE RANDOMIZED TO YOGA (N = 19) OR TO USUAL CARE (N = 21). WOMEN IN THE YOGA GROUP REPORTED SIGNIFICANTLY LOWER TOTAL MENOPAUSAL SYMPTOMS COMPARED WITH THE USUAL CARE GROUP AT WEEK 12 (MEAN DIFFERENCE, -5.6; 95% CONFIDENCE INTERVAL, -9.2 TO -1.9; P = .004) AND AT WEEK 24 (MEAN DIFFERENCE, -4.5; 95% CONFIDENCE INTERVAL, -8.3 TO -0.7; P = .023). AT WEEK 12, THE YOGA GROUP REPORTED LESS SOMATOVEGETATIVE, PSYCHOLOGICAL, AND UROGENITAL MENOPAUSAL SYMPTOMS; LESS FATIGUE; AND IMPROVED QUALITY OF LIFE (ALL P < .05). AT WEEK 24, ALL EFFECTS PERSISTED EXCEPT FOR PSYCHOLOGICAL MENOPAUSAL SYMPTOMS. SHORT-TERM EFFECTS ON MENOPAUSAL SYMPTOMS REMAINED SIGNIFICANT WHEN ONLY WOMEN WHO WERE RECEIVING ANTIESTROGEN MEDICATION (N = 36) WERE ANALYZED. SIX MINOR ADVERSE EVENTS OCCURRED IN EACH GROUP. CONCLUSIONS: YOGA COMBINED WITH MEDITATION CAN BE CONSIDERED A SAFE AND EFFECTIVE COMPLEMENTARY INTERVENTION FOR MENOPAUSAL SYMPTOMS IN BREAST CANCER SURVIVORS. THE EFFECTS SEEM TO PERSIST FOR AT LEAST 3 MONTHS. 2015 20 1818 39 PROSPECTIVE RANDOMIZED TRIAL OF STANDARD ANTIEMETIC THERAPY WITH YOGA VERSUS STANDARD ANTIEMETIC THERAPY ALONE FOR HIGHLY EMETOGENIC CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN SOUTH ASIAN POPULATION. AIM/BACKGROUND: CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IS ONE OF THE MOST DISTRESSING SIDE EFFECTS OF HIGHLY EMETOGENIC CHEMOTHERAPY REGIMENS. THERE HAVE BEEN CONTINUOUS EFFORTS IN THE DIRECTION TO CONTROL CINV BY MANY INVESTIGATORS. MATERIALS AND METHODS: RANDOMLY SELECTED PATIENTS WERE THOSE RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY REGIMEN GROUPED INTO YOGA AND STANDARD ANTIEMETIC THERAPY (N = 50) JUST BEFORE RECEIVING CHEMOTHERAPY AND CONTINUED FOR THE FOLLOWING DAYS AND OTHER GROUP (N = 50) RECEIVED ONLY THE STANDARD ANTIEMETIC AGENT. BOTH THE GROUPS WERE ASSESSED, FOLLOWED FOR ACUTE AND DELAYED ONSET OF CHEMOTHERAPY-INDUCED AND ANTICIPATORY NAUSEA AND VOMITING USING RADIATION THERAPY ONCOLOGY GROUP GRADING FOR THE SAME. WE ALSO ASSESSED THE QUALITY OF LIFE OF THE PATIENT USING THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL QUESTIONNAIRE. RESULTS: THE MEDIAN AGE GROUP OF THE PATIENTS WAS 51 YEARS WITH MALE:FEMALE RATIO 2:1, THE EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS WAS 0/1 IN 38% OF THE SELECTED POPULATION, WHILE ECOG 2 IN 62% OF THE PATIENTS. IN YOGA ARM, INSIGNIFICANT REDUCTION IN CHEMOTHERAPY-INDUCED NAUSEA (90% VS. 78%, P = 0.35) AND BUT SIGNIFICANT REDUCTION IN VOMITING (42% VS. 22%, P =0.01) WAS OBSERVED AS COMPARED TO THE STANDARD ANTIEMETICS ONLY ARM. THERE WAS A SIGNIFICANT REDUCTION IN GRADE 2 AND 3 NAUSEA (84% VS. 38% P < 0.01) AND VOMITING (14% VS. 0% P < 0.01). QUALITY OF LIFE IS ALSO SIGNIFICANTLY IMPROVED IN THE YOGA ARM, ESPECIALLY IN THE ECOG 2 PERFORMANCE STATUS. CONCLUSIONS: THIS STUDY CONCLUDES THAT YOGA ALONG WITH STANDARD ANTIEMETIC MEDICATION SHOULD BE A PART OF THE MANAGEMENT PLAN FOR THE CANCER PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY. 2019